Cargando…

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients

Detalles Bibliográficos
Autores principales:	Weinhold, Niels, Salwender, Hans J., Cairns, David A., Raab, Marc S., Waldron, George, Blau, Igor W., Bertsch, Uta, Hielscher, Thomas, Morgan, Gareth J., Jauch, Anna, Davies, Faith E., Hänel, Mathias, Cook, Gordon, Scheid, Christoph, Houlston, Richard, Goldschmidt, Hartmut, Jackson, Graham, Kaiser, Martin F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485656/ https://www.ncbi.nlm.nih.gov/pubmed/34092058 http://dx.doi.org/10.3324/haematol.2021.278888

Ejemplares similares

An internet survey of 2,596 people with fibromyalgia
por: Bennett, Robert M, et al.
Publicado: (2007)

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
por: Hose, Dirk, et al.
Publicado: (2019)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
por: Emde-Rajaratnam, Martina, et al.
Publicado: (2023)

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
por: Merz, Maximilian, et al.
Publicado: (2017)

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
por: Merz, Maximilian, et al.
Publicado: (2019)

P879: EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA
por: Huhn, S., et al.
Publicado: (2022)

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells
por: Meißner, Tobias, et al.
Publicado: (2015)

Selective elimination of immunosuppressive T cells in patients with multiple myeloma
por: Awwad, Mohamed H. S., et al.
Publicado: (2021)

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2020)

Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2021)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

The prognostic significance of [(18)F]FDG PET/CT in multiple myeloma according to novel interpretation criteria (IMPeTUs)
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial
por: Huhn, S, et al.
Publicado: (2017)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
por: Schmitt, Michael, et al.
Publicado: (2016)

Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
por: Salwender, Hans, et al.
Publicado: (2019)

Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma
por: Johnson, David C., et al.
Publicado: (2016)

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial
por: Klein, Eva-Maria, et al.
Publicado: (2021)

Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma
por: Chattopadhyay, Subhayan, et al.
Publicado: (2019)

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis
por: Khandanpour, Cyrus, et al.
Publicado: (2021)

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
por: Stroh, Jacob, et al.
Publicado: (2022)

2596. Invasive Fungal Disease in Patients with GATA2 Variant Hematologic Malignancy
por: Bold, Tyler D, et al.
Publicado: (2019)

Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop
por: Lutz, Raphael, et al.
Publicado: (2021)

The Glycome of Normal and Malignant Plasma Cells
por: Moehler, Thomas M., et al.
Publicado: (2013)

Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
por: Kriegsmann, Katharina, et al.
Publicado: (2020)

Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression
por: Li, Ni, et al.
Publicado: (2016)

Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM
por: Kriegsmann, Katharina, et al.
Publicado: (2022)

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
por: Weisel, Katja C., et al.
Publicado: (2019)

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
por: Leypoldt, Lisa B., et al.
Publicado: (2023)

A systematic classification of death causes in multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2018)

Can (18)F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?
por: Sachpekidis, Christos, et al.
Publicado: (2020)

PB2596: OPTIMIZING PLATELET TRANSFUSION FOR CLINICAL PRACTICE. DO PLATELETS AGE MATTER FOR THERAPEUTIC PLATELETS TRANSFUSION?
por: Attallah, Samy, et al.
Publicado: (2023)

Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2016)

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
por: Leypoldt, Lisa B., et al.
Publicado: (2021)

Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma
por: Mitchell, Jonathan S., et al.
Publicado: (2015)

596 Application of Intravenous Immunoglobulin for Treatment of Chronic Autoimmune Urticaria
por: Alyoshkin, Vladimir
Publicado: (2012)

Genetic factors influencing the risk of multiple myeloma bone disease
por: Johnson, D C, et al.
Publicado: (2016)

Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema
por: Padilha, Gisele A., et al.
Publicado: (2015)

Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma
por: Wu, Xiaowen, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sre0f5f3nrpqnbiuk0novgpt0v